Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.

Blockade of IL-23: What is in the Pipeline?

Open access
Parigi, Tommaso Lorenzo, Iacucci, Marietta, Ghosh, Subrata · 2022 · Journal of Crohn's and Colitis

Abstract

Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn’s disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ecco-jcc/jjab185

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Overview of IL12 and IL23’s pathways in the pathogenesis of inflammatory bowel disease.
Figure 1. Overview of IL12 and IL23’s pathways in the pathogenesis of inflammatory bowel disease.CC BY-NC · PubMed Central
Figure 2. Overview of agents targeting the IL12-IL23 pathway.
Figure 2. Overview of agents targeting the IL12-IL23 pathway.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

9 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 5

  1. Hong, 2021, Real, Crohns Colitis 360, 3
  2. D’Haens, 2021, Risankizumab induction therapy in patients with moderate-to-severe Crohn’s disease with intolerance or inadequate response to conventional and/or biologic therapy: results from the phase 3 advance study, E28
  3. Bossuyt, 2021, Risankizumab therapy induces improvements in endoscopic endpoints in patients with moderate-to-severe Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE studies, S033
  4. Schreiber, 2021, Risankizumab induces early clinical remission and response in patients with moderate-to-severe Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE studies, S026
  5. Lichtenstein, 2020, Impact of Mirikizumab treatment on health-related quality of life in patients with ulcerative colitis: a phase 2 study analysis using the SF-36 V2 Standard, Gastroenterology, 158, S-S-1205

Cited by

See all 93

Metadata

Authors
Parigi, T. L., Iacucci, M., & Ghosh, S.
Affiliations
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • University College Cork (IE)
Corresponding author
Ghosh, Subrata
Venue
Journal of Crohn's and Colitis
Published
2022-04-01
Volume
16
Issue
Supplement_2
Pages
ii64-ii72
ISSN
  • 1873-9946 (ISSN-L)
  • 1876-4479
OpenAlex
W4230705380
Cited by
93
References
65
Citations by year
2026: 9 · 2025: 27 · 2024: 25 · 2023: 26 · 2022: 6
FWCI
2.10
Type
journal article
Language
en
Open access
Locations
  • Journal of Crohn s and Colitis (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
AbbVie
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
IL-23
MeSH terms
Ustekinumab, Colitis, Ulcerative, Crohn Disease, Humans, Inflammatory Bowel Diseases, Interleukin-23

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blockade of IL-23: What is in the Pipeline? https://app.cochat.ai/papers/10.1093/ecco-jcc/jjab185
The paper
Parigi, T. L., Iacucci, M., & Ghosh, S. (2022). Blockade of IL-23: What is in the Pipeline? Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjab185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.